Sources:
- Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230-40.,Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419-23.,Ohno S, Siddik ZH, Kido Y, et al. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol. 1994;34:302-6.,Panteix G, Beaujard A, Garbit F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res. 2002;22(2B):1329-36.,Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256-60.,van de Vaart PJ, van der Vange N, Zoetmulder FA, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34:148-54.,Spriggs DR, Zivanovic O. Ovarian cancer treatment — are we getting warmer? N Engl J Med. 2018;378:293-4.,Vergote I, Chiva L, du Bois A. Commentary. New Engl J Med. 2018;378:1362-3.,Fotopoulou C, Sehouli J, Mahner S, et al. HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol. 2018;29:1610-3.,Harter P, du Bois A, Sehouli J, et al. Is there a role for HIPEC in ovarian cancer. Arch Gynecol Obstet. 2018;298:859-60.,Du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCOG OCCC2004). Ann Oncol. 2005; 16 (suppl 8), viii7-viii12.,Alyami M, Kim BJ, Villeneuve L, et al. Ninety-day post-operative morbidity and mortality using National Cancer Institute’s common terninalogy criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia. 2018;34:532-7.,Lim MC, Chang S-J, Yoo HJ, et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol. 2017;35 (suppl); abstract #5520.,Ledermann JA, Raja FA, Fotopoulou C, et al. on behalf of the ESMO Guidelines Working Party. Ann Oncol. 213;24 (suppl 6): vi24-vi32.